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Executive Summary
It is widely believed that firms pursuing product modification strategies require one set of
control mechanisms and that firms pursuing new product strategies require a different set of
control mechanisms (Dewar & Dutton, 1986; Ettlie, Bridges, & O'Keefe, 1984; Kaluzny,
Veney, & Gentry, 1984). However, few studies have examined the role of innovation
strategies and control mechanisms in the innovation creation process. Using data from 45
pharmaceutical firms I investigated the effects of innovation strategies and formal control
mechanisms on innovation outcomes. The findings suggest the following:
•

First, strategic intent does not have a direct effect on innovation outcomes as
hypothesized. Theories that focus on intended strategies did not receive support in
this study. These results are consistent with the recent anecdotal evidence in
business publications that suggest that the desire to be innovative and the
commitment of innovation-targeted resources does not help organizations realize
innovation outcomes (O'Reilly, 1991; Vanston, 1988).

•

Second, it appears that control plays a more critical role than expected in the
innovation creation process. Control mechanism effects were clear and systematic,
although, not always supporting the hypotheses based on the literature. The results
suggest that the innovation process is not stochastic and that managers can use
formal control mechanisms to proactively guide the process.

•

Third, the determinants of product modifications and new products do not appear to
be different. All three types of control mechanisms, input, process, and output,
were found to be positively related to both the number of product mcxlifications and
new products.

•

Fourth, although strategic intent did not have a direct effect on innovation
outcomes, it does have an indirect effect on innovation outcomes through control
mechanisms. Although not explicitly tested in this research, strategic intent had a
direct effect on control mechanisms, which in turn affected innovation outcomes.
The results clearly suggest that managers must choose control mechanisms that
support innovation strategies.

References:

Dewar & Dutton, Management Science, (vol. 32), pp. 1422-1433; Ettlie, Bridges, & O'Keefe,
Management Science (vol. 30), pp. 682-695; Kaluzny, Veney, & Gentry, Health and Society
(vol. 52), pp. 51-82; O'Reilly, Fortune, June 3, pp. 48-63; Vanston, Business Week, June 13,
pp. 8.

Purpose of the Study
Although innovation strategies (strategic goals) and realized innovation outcomes (product
modifications and new products) represent different endpoints of the innovation process,
little empirical work exists that has attempted to link innovation strategies and innovation
outcomes. The overall purpose of this research was to study formal mechanisms that
managers can use to influence the innovation process in their R&D laboratories to
successfully realize innovation goals. More specific subgoals are listed as follows:
•

First, this project examines the determinants of the innovation creation process in
R&D laboratories. Prior research examining the determinants of innovation
has focused on innovation adoption (e.g., once the NOW checking account
was created at one bank, NOW accounts were adopted by the rest of the banking
industry), but not innovation creation. Researchers examining innovation creation
have described innovations across a product's life cycle (e.g., automobiles, starting
with the Ford Model T), but not the determinants of the technical innovations
themselves (Abernathy & Clark, 1988; Tushman & Anderson, 1986).

•

Second, the project examines the match between innovation strategies and control
mechanisms and their corresponding affects in achieving product modifications
versus new products. It was hypothesized that different innovation strategies (the
strategic intent to pursue product modifications versus the strategic intent to pursue
new products) require differential control mechanisms. Specifically, it was
expected one set of control mechanisms would enhance the pursuit of product
modifications, and that the same set of control mechanisms would hamper the
pursuit of new products.

•

Third, the project examines a more encompassing set of control mechanisms than
previously studied. Although process control mechanisms (targeting behaviors and
activities) have been the most studied type of control, they also have been the least
recommended form of control when the transformation process is uncertain; for
example in the research and development process. Therefore this project also
looked at input controls (specialist diversity, specialist depth, and
professionalization) and output controls (goal specificity, emphasis on outcomes in
evaluation, and rewards and bonuses linked to results), in addition to process
controls (centralization, documentation, formalization, frequency of performance
appraisals).
·

References:

Abernathy & Clark, In Tushman & Moore (Eds.), Readings in the Management of Innovation.
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Definitions
Strate~c

Intent Variables

•

Strategic Intent to Pursue New Products/Drugs -The extent to which top management emphasizes new
product development as a vital element of its strategy and as a means to compete.

•

Strategic Intent to Pursue Product Modifications -The extent to which top management emphasizes
improvements to existing products as a vital element of its strategy and as a means to compete.

•

R&D Spending/Sales- average R&D spending as a percentage of sales for 1979-83.

•

Targeted Percent of Sales from New Products- Targeted percentage of sales from new products for 1979-83.

Organizational Control Variables
•

Use of Input Control Mechanisms- The extent to which control mechanisms control for the degree and
variety of core knowledge, skills, experiences, and attitudes displayed on the job for R&D professionals.
•• Specialist Diversity - the number of different scientific specialties
•• Special Depth - the degree to which personnel are concentrated in a few core specialities.
•• Professionalization - the number of years of specialized schooling and the propensity to seek contact
with professional colleagues outside the immediate work setting.

•

Use of Process Control Mechanisms- The extent to which control mechanisms are used to regulate and
monitor activities and behaviors displayed by R&D professionals.
•• Centralization - the degree of decision-making authority at lower levels of the organization hierarchy.
•• Documentation - the amount of record-keeping of work behaviors required by R&D professionals.
•• Formalization - the extent that rules governing behavior are precisely and explicitly formulated.
•• Frequency of Performance Appraisals- the number of times behavior is measured and evaluated.

•

Use of Output Control Mechanisms- The extent to which control mechanisms are used to control results
and outcomes produced by R&D professionals.
•• Goal Specificity- the extent to which goals are explicitly, clearly defined, and provide
unambiguous criteria for selecting among alternative outcomes.
•• Rewards and Bonuses Linked to Results - the degree of public recognition R&D professionals
receive for outstanding achievements.
•• Emphasis on Outcomes - the degree to which the quantity of outcomes is emphasized in
performance appraisals and rewards.

Innovation Variables

• New Products- were drugs approved by the FDA representing chemical structures never previously available
in the U.S. to treat a particular disease (New Chemical Entities).

•

Product Modifications- were drugs involving new dosage forms, new indications, formula changes, name
changes, and status changes.

Research Method
Sample and Sample Selection
A comprehensive list of U.S. pharmaceutical firms was developed using multiple sources:
the National Pharmaceutical Council's membership list, the Pharmaceutical Manufacturers
Association's membership list, the Generic Association's membership list, Medical
Advertisin~ News (Top 50 Pharmaceutical Firms Special Issue), Paul de Haen's New
Product Survey and New Product Index, Pharmaceutical Manufacturers of the United
~. R&D Laboratories in the U.S., Physician's Desk Reference, and Approved Dru~
Products with Therapeutic Equivalence Evaluations. After excluding firms that no longer
existed, were duplicate listings, or had no in-house R&D, a final sample population of 154
firms remained. Fifty-five agreed to participate and provided full or partial data,
constituting a response rate of 35.71%. Forty-five complete sets of questionnaires were
completed by both the CEO (or a Senior Level Manager) and R&D Director and used for
this study. Fourteen of the firms in the sample were members of the National
Pharmaceutical Council.
Data Collection
Two primary types of data collection methods were used for this study: archival data
collection and questionnaire data collection methods. An archival data methodology was
used to collect data for innovation outcomes. A questionnaire methodology was used to
collect data for strategic intent and control mechanisms.
Innovation data was collected from archival sources from 1984-1988. CEOs were asked
retrospective questions concerning strategic intent to innovate during 1979-1983. R&D
Directors were asked retrospective questions concerning control mechanisms in their firms'
R&D laboratories during 1979-1983.

Sample Characteristics

Average

Range

Senior Level Manager Characteristics
Years in Current Position
Years in Firm
Years in Industry

7.24
14.18
17.70

1.00
2.00
2.00

to
to
to

31.00
31.00
36.00

R&D Director Characteristics
Years in Current Position
Years in Firm
Years in Industry

6.47
13.58
18.29

1.00
1.00
1.00

2722.68
14.90
9.90
.87
3.56

11.00
-2.50
-2.50
0.00
0.00

to 31,500
to 42.45
to 42.45
to 11.00
to 14.00

370.87
12.45
22.45

1.00
2.45
2.45

to 3356.00
to 32.45
to 52.45

to
to
to

36.00
37.00
37.00

Business Unit Characteristics
Number of Employees
ROI
ROA
Number of New Products (NCEs)
Number of Product Modifications
R&D Laboratory Characteristics
Number of Employees in R&D Laboratory(ies)
R&D Spending/Sales
Targeted Percent of Sales from New Products

Primary Findings

Influence of Strategic Intent on the Number of
Product Modifications and New Products

Do pharmaceutical firms with a higher level of commitment to product
modifications exhibit a greater number of product modifications and new
products?

I Average Level of Strategic Intent to Pursue Product Modifications I
Product Modifications

~LOW
New Products

•

0.00

10.00

HIGH

20.00

Do pharmaceutical firms with a higher level of commitment to new products
exhibit a greater number of product modifications and new products?

I Average Level of Strategic Intent to Pursue New Products I
Product Modifications

~LOW
New Products
I

0.00

.HIGH

I

I

2.00

4.00

6.00

Influence of Strategic Intent on the Number of
Product Modifications and New Products
(continued)

Do pharmaceutical firms that spend a higher level of R&D spending as a
percentage of sales exhibit a greater number of product modifications and new
products?

I Average Level of R&D Spending as a Percentage of Sales I
Product Modifications

~LOW
New Products

.HIGH

I

I

I

I

0.00

I

I

I

I

I

5.00

I

I

I

I

10.00

I

15.00

Do pharmaceutical firms that target a higher percentage of sales to be
generated from new products exhibit a greater number of product
modifications and new products?

I Average Percentage of Sales to Be Generated from New Products I
Product Modifications

~LOW
New Products

.HIGH
I

0.00

I

I

I

I

10.00

I

I

I

I

20.00

I

I

I

30.00

Influence of Strategic Intent on the Number of
Product Modifications and New Products
(continued)

Comments:
In general, there were few differences between pharmaceutical firms with
respect to achieving higher level of product modifications and new products
for the strategic intent variables. The only exception was that firms that
exhibited higher levels of commitment to new products exhibited a higher
level of product modifications (note that this was the only statistically
significant finding for the strategic intent variables).

Influence of Input Control Mechanisms on the Number of
Product Modifications and New Products

Do pharmaceutical firms with higher levels of specialist diversity in their R&D
laboratories exhibit a greater number of product modifications and new
products?

I Average Level of Specialist Diversity I
Product Modifications

~LOW
New Products

.HIGH

20.00

0.00

40.00

Do pharmaceutical firms with higher levels of specialist depth in their R&D
laboratories exhibit a greater number of product modifications and new
products?

I Average Level of Specialist Depth I
Product Modifications

~LOW
New Products

.HIGH
I

0.00

I

I

I

I

I

50.00

100.00

Influence of Input Control Mechanisms on the Number of
Product Modifications and New Products
(continued)

Do pharmaceutical firms with higher levels of professionalization in their R&D
laboratories exhibit a greater number of product modifications and new
products?

IAverage Level of Professionalization I
Product Modifications

~LOW
New Products

.HIGH
I

0.00

I

I

I

I

50.00

I

I

I

100.00

Comments:
Pharmaceutical firms with higher levels of specialist diversity and
professionalization and lower levels of specialist depth exhibited higher
levels of product modifications and new products (note that effects of specialist
diversity, specialist depth, and professionalization on product
modifications and new products were statistically significant).

Influence of Process Control Mechanisms on the Number of
Product Modifications and New Products

Do pharmaceutical firms with higher levels of centralization in their R&D
laboratories exhibit a greater number of product modifications and new
products?

I Average Level of Centralization I
Product Modifications

~LOW
New Products

.HIGH
I

I

I

0.00

I

I

20.00

40.00

60.00

Do pharmaceutical firms with higher levels of documentation in their R&D
laboratories exhibit a greater number of product modifications and new
products?

I Average Level of Documentation I
Product Modifications

~LOW
New Products
I

0.00

I

.HIGH

I

I

20.00

40.00

Influence of Process Control Mechanisms on the Number of
Product Modifications and New Products
(continued)

Do pharmaceutical firms with higher levels of formalization in their R&D
laboratories exhibit a greater number of product modifications and new
products?

I Average Level of Formalization I
Product Modifications

~LOW
New Products

0.00

.HIGH

10.00

20.00

Do pharmaceutical firms with higher levels of frequency of performance
appraisals in their R&D laboratories exhibit a greater number of product
modifications and new products?

IAverage Level of Frequency of Performance Appraisals I
I

Product Modifications

~LOW
New Products

•
I

0.00

10.00

20.00

I

30.00

HIGH

Influence of Process Control Mechanisms on the Number of
Product Modifications and New Products
(continued)

Comments:
Pharmaceutical firms with higher levels of centralization, documentation,
formalization, and frequency of performance appraisals exhibited higher
levels of product modifications and new products (note that effects of
documentation and frequency of performance appraisals on product
modifications and new products were statistically significant, while
centralization and formalization were not).

Influence of Output Control Mechanisms on the Number of
Product Modifications and New Products

Do pharmaceutical firms with higher levels of goal specificity in their R&D
laboratories exhibit a greater number of product modifications and new
products?

I Average Level of Goal Specificity I
Product Modifications

~LOW
New Products

•
I

0.00

I

I

I

I

I

I

20.00

I

I

I

I

40.00

HIGH

I

60.00

Do pharmaceutical firms with a greater emphasis on outcomes in their R&D
laboratories exhibit a greater number of product modifications and new
products?

I Average Level of Emphasis on Outcomes I
Product Modifications

~LOW
New Products

.HIGH
I

0.00

10.00

I

I

20.00

I

I

I

30.00

Influence of Output Control Mechanisms on the Number of
Product Modifications and New Products
(continued)

Do pharmaceutical firms with higher levels of rewards and bonuses linked to
results in their R&D laboratories exhibit a greater number of product
modifications and new products?

IAverage Level of Rewards and Bonuses Linked to Results I
Product Modifications
New Products

=::::::=:-

~LOW

==:=:::t:-•
I

0.00

I

I

I

I

20.00

I

I

I

1-

40.00

I

I

.HIGH
I

60.00

Comments:
Pharmaceutical firms with higher levels of goal specificity, emphasis on
outcomes, and rewards and bonuses linked to results exhibited higher
levels of product modifications and new products (note that effects of
emphasis on outcomes and rewards and bonuses linked to results on product
modifications and new products were statistically significant, while goal
specificity was not).
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